ARWR
ARROWHEAD PHARMACEUTICALS, INC.
+2.44 (+3.71%)68.23USD1.4M成交股數9.6B市值–本益比(近四季)14.4股價營收比+171.0%營收年增(近四季)2026-11-24下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 9 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 75.3M-86% | 73.7M+2849% | 264M | 27.8M | 543M | 2.5M-30% | 0.00-100% | 0.00-100% | 0.00 | 3.6M | 15.8M | 146M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 198M | 173M | 177M | 162M | 133M | 137M | 136M | 152M | 101M | 116M | 94.8M | 74.9M |
| 銷售管理費用 | 47.1M | 41.7M | 46.0M | 30.9M | 28.4M | 26.9M | 26.4M | 23.7M | 25.1M | 23.6M | 23.8M | 23.2M |
| 營業利益 | −170M-145% | −141M-12% | 40.8M-125% | −166M-6% | 381M-402% | −161M+18% | −162M+58% | −176M-466% | −126M | −137M | −103M | 48.2M |
| 營業利益率 | -226.0% | -191.6% | 15.5% | -596.2% | 70.2% | -6,456.5% | – | – | – | -3,845.3% | -649.0% | 32.9% |
| 稅後淨利 | −194M-152% | −133M-23% | 30.8M-118% | −175M+3% | 370M-396% | −173M+30% | −171M+66% | −171M-451% | −125M | −133M | −103M | 48.7M |
| 淨利率 | -258.2% | -180.0% | 11.7% | -631.1% | 68.3% | -6,923.4% | – | – | – | -3,741.6% | -650.5% | 33.3% |
| 稀釋 EPS | -1.36-149% | -0.93-33% | 0.22-116% | -1.26-9% | 2.75-370% | -1.39+12% | -1.36+42% | -1.38-407% | -1.02 | -1.24 | -0.96 | 0.45 |
| 稀釋股數 | 143M | 142M | 141M | 139M | 134M | 125M | 120M | 124M | 123M | 107M | 107M | 108M |
資產負債表 期末餘額
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 54.8M | 189M | 202M | 130M | 186M | 53.9M | 103M | 69.4M | 128M | 58.2M | 105M | 135M |
| 應收帳款 | 8.6M | 15.7M | 219M | 9.7M | 2.4M | 2.5M | 0.00 | – | – | – | 1.2M | 69.4M |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 2.1B | 2.3B | 1.6B | 1.4B | 1.6B | 1.0B | 1.1B | 884M | 955M | 626M | 796M | 891M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 股東權益 | 466M | 614M | 568M | 522M | 683M | 52.6M | 185M | 331M | 484M | 160M | 365M | 447M |
| 負債比 | – | – | – | – | – | – | – | – | – | – | – | – |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | – | 13.5M | – | – | −146M+24% | – | – | – | −118M | – | – |
| 資本支出 | – | – | 2.1M | – | – | 7.5M | – | – | – | 68.7M | – | – |
| 自由現金流 | – | – | 11.3M | – | – | −154M-18% | – | – | – | −186M | – | – |
| 折舊攤銷 | 6.2M | 5.9M | 6.0M | 5.8M | 5.6M | 4.8M | 4.6M | 4.4M | 4.1M | 3.8M | 2.9M | 2.2M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | 4.3% | – | – | -6,151.5% | – | – | – | -5,251.9% | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
主要客戶2025 年度 · 829M
| Sarepta Therapeutics Inc | 697M | 84.0% | – |
|---|---|---|---|
| Sanofi | 130M | 15.7% | – |
| Glaxosmithkline Intellectual Property Limited | 2.6M | 0.3% | -1.5% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 829M | +23258.2% | −1.6M | -0.2% | -0.01 | 157M |
| FY2024 | 3.6M | -98.5% | −599M | -16,882.4% | -5.00 | −604M |
| FY2023 | 241M | -1.0% | −205M | -85.3% | -1.92 | −331M |
| FY2022 | 243M | +75.9% | −176M | -72.4% | -1.67 | −189M |
| FY2021 | 138M | +57.2% | −141M | -101.9% | -1.36 | 148M |
| FY2020 | 88.0M | -47.9% | −84.6M | -96.1% | -0.84 | −108M |
| FY2019 | 169M | +945.7% | 68.0M | 40.3% | 0.69 | 161M |
| FY2018 | 16.1M | – | −54.5M | -337.3% | -0.65 | −48.6M |